Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 9, 2013, Pages 1172-1175

  Kroon, M W ^a   Kemp, E Helen ^b   Wind, B S ^a   Krebbers, G ^a   Bos, J D ^a   Gawkrodger, D J ^c   Wolkerstorfer, A ^a   Van Der Veen, J P Wietze ^a,d   Luiten, R M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MONOPHENOL MONOOXYGENASE; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; IN VITRO STUDY; MALE; PERNICIOUS ANEMIA; PREVALENCE; PRIORITY JOURNAL; SARCOIDOSIS; VITILIGO;

ADULT; ANTIGENS; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MELANOCYTES; MIDDLE AGED; VITILIGO; YOUNG ADULT;

EID: 84881145879     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04501.x     Document Type: Article

References (20)

1. Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008; 17: 139-140.
2. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-2232.
3. Kemp EH, Gawkrodger DJ, MacNeil S, et al. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997; 109: 69-73.
4. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139: 798-805.
5. Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109: 923-930.
6. Naughton GK, Eisinger M, Bystryn JC,. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81: 540-542.
7. Naughton GK, Eisinger M, Bystryn JC,. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158: 246-251.
8. Harning R, Cui J, Bystryn JC,. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-1080.
9. Kemp EH, Emhemad S, Akhtar S,. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 2011; 20: 35-40.
10. Naughton GK, Reggiardo MD, Bystryn JC,. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-981.
11. Yu HS, Kao CH, Yu CL,. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental vitiligo. J Invest Dermatol 1993; 100: 823-828.
12. Njoo MD, Westerhof W,. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-181.
13. Fongers A, Wolkerstorfer A, Nieuweboer-Krobotava L, et al. Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. Br J Dermatol 2009; 161: 1105-1111.
14. Njoo MD, Das PK, Bos JD, et al. Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 1999; 135: 407-413.
15. Kemp EH, Gawkrodger DJ, Watson PF, et al. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients; a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114: 333-338.
16. Waterman EA, Kemp EH, Gawkrodger DJ, et al. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/Mart1. Clin Exp Immunol 2002; 129: 527-532.
17. Tsukamoto K, Jackson IJ, Urabe K, et al. A second tyrosinase-related protein, TRP2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J 1992; 11: 519-526.
18. Schreurs MJW, de Boer AJ, Schmidt A, et al. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res 1997; 7: 463-470.
19. Levy-Marchal C, Bridel MP, Sodoyez-Goffaux F, et al. Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type I diabetic children. Diabetes Care 1991; 14: 61-3.
20. Candon S, Mauvais FX, Garnier-Lengliné H, et al., Monitoring of Antitransglutaminase Autoantibodies in Paediatric Celiac Disease Using a Highly Sensitive Radiobinding Assay. J Pediatr Gastroenterol Nutr 2012; 54: 392-396.